Market Performance Snapshot
Actinium (ATNM) closed the latest trading session at USD 1.37, marking a +6.06 % gain over the preceding 24‑hour period that concluded at 04:06 PM Central Europe on Wednesday, 21 March 2026. The current free float stands at 31.4 million shares, with a market capitalization of USD 41.5 million. Trading volume for the last day reached USD 1.3 million, reflecting a moderate liquidity profile relative to its peers.
Relative to the month‑end, the share price has risen 16.67 %. Over a longer horizon, the 200‑day simple moving average sits at USD 1.12, while the 52‑week high and low are USD 1.74 (24 Oct 2025) and USD 0.74 (05 Aug 2026), respectively.
Clinical Breakthrough at EANM
At the European Association of Nuclear Medicine congress, Actinium Pharmaceuticals announced the first‑in‑human Phase I data for ATNM‑400, an Actinium‑225 antibody radioconjugate targeting HER3. Early safety profiling from the initial dose cohort revealed no clinically significant adverse events, and the program has advanced to a higher dose level. This progress signals sustained commitment to the therapeutic trajectory for metastatic castration‑resistant prostate cancer.
Simultaneously, the company showcased pre‑clinical evidence that ATNM‑400 suppresses tumor growth across a spectrum of solid‑tumor models—including non‑small‑cell lung cancer, colorectal cancer, and ovarian cancer—while potentiating the efficacy of standard chemotherapeutic agents. By pivoting from the conventional PSMA‑targeted paradigm to a HER3‑directed approach, Actinium positions ATNM‑400 as a pan‑tumor radiotherapy platform, adaptable to both monotherapy and combination regimens.
Peer Performance Overview
| Ticker | 24‑h Change | Current Price (USD) | Market Cap (USD mn) |
|---|---|---|---|
| MDAI | –0.66 % | 1.51 | 48.9 |
| SCOR | +5.20 % | 3.41 | 49.7 |
| CULP | –0.26 % | 3.63 | 49.0 |
| CRBU | +11.85 % | 0.54 | 49.7 |
| MYO | +0.80 % | 1.28 | 49.5 |
Actinium’s contemporaneous peers exhibit a mixed landscape, with Caribou Biosciences leading gains and Spectral Ai trailing modestly. The comparative performance underscores Actinium’s relative momentum amid a competitive clinical‑stage biotech cohort.
Strategic Outlook
Actinium’s recent clinical data, coupled with a robust valuation trajectory, suggests a trajectory of accelerated value creation. The company’s focus on antibody‑radioconjugate innovation aligns with a broader market demand for precision oncology solutions. As ATNM‑400 proceeds through higher‑dose cohorts and expands into combination protocols, the potential for incremental revenue streams and partnership opportunities will likely solidify its position within the targeted therapy ecosystem.
With a clear scientific roadmap and a demonstrable safety profile, Actinium is poised to capitalize on unmet clinical needs, thereby advancing its mission to revolutionize treatment paradigms across oncology.
